Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

AbbVie Inc ABBV stock is trending on Tuesday after the U.S. drug giant announced that key data from its broad oncology ...

AbbVie is sprinting beyond its Humira dependency by banking on rising stars Skyrizi and Rinvoq, which are smashing sales ...

RS Investments, an investment management company, released its “RS Large Cap Value Strategy” first quarter 2025 investor ...

AbbVie scored a courtroom win as an Illinois appellate court dismissed a $63 billion shareholder lawsuit over its 2020 ...

AbbVie Inc. (NYSE: ABBV) has achieved a significant legal victory as the Illinois Appellate Court upheld the dismissal of a ...

Fintel reports that on May 14, 2025, Citigroup downgraded their outlook for AbbVie (NYSE:ABBV) from Buy to Neutral. Analyst ...

Top 12 Stock Recommendations. In this article, we will take a look at where AbbVie Inc. (NYSE:ABBV) stands against other top stock recommendations by ChatGPT. After a two-year surge of 53% ...

Rob Stothard / Bloomberg via Getty Images AbbVie's first-quarter sales and adjusted earnings per share topped estimates. The drugmaker lifted its full-year adjusted EPS forecast by 10 cents.

Today, AbbVie's stock sits roughly 20% off its highs. It's a good time to take a breather, assess the underlying business, and consider whether the stock's decline offers enough value to make ...